The GLP-1 agonists market is set to skyrocket, reaching USD 170.75 billion by 2033, growing from USD 64.42 billion in 2025 at ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) announced results from its Phase Ib ...

A growing body of research and experts have suggested that GLP-1s can be powerful tools for midlife women. Here’s what we ...

Expanded use of GLP-1 drugs may lead to more side effects, already the subject of thousands of lawsuits now moving through ...

A recent study found that Glucagon-like peptide-1 (GLP-1) receptor agonist use in hypertrophic cardiomyopathy (HCM) patients ...

GLP-1 agonists are pivotal in obesity care, promoting weight loss and addressing related health issues, with a focus on ...

Danish pharmaceutical manufacturer Novo Nordisk on Dec. 22 announced that the U.S. Food and Drug Administration (FDA) has ...

GLP-1 agonists like Ozempic are primarily used to treat type 2 diabetes. Its popularity has even influenced wholesale retailer Costco to sell Ozempic and Wegovy (another popular semaglutide) at its ...

Researchers are studying whether these widely used weight-loss drugs may also be future treatments for alcohol abuse.

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 ...

CMS released plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The announcement comes weeks following the White House’s ...

Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...